Skip to content

Cochlear Implant Low Power Strategy

Clinical Assessment of a Low Power Strategy for Cochlear Implant Recipients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02879539
Enrollment
32
Registered
2016-08-25
Start date
2015-03-31
Completion date
2017-01-27
Last updated
2021-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hearing Loss

Keywords

cochlear implants, power consumption,

Brief summary

Reducing power consumption in the cochlear implant is crucial to the development of future smaller sound processors. The commercial MP3000 sound coding strategy has been shown to be more efficient in power consumption to the standard ACE strategy. However in order to develop smaller sound processors, further battery life power savings are required. The aim of this study is to evaluate three experimental sets of MP3000 parameter sets, compared against the default ACE program. In the background for each of the four strategies, experimental noise reduction programs (SpatialNR and NR3) will also be in use. In an additional phase of the study, low stimulation rate ACE programs will also be evaluated against the default stimulation rate.

Interventions

DEVICEMP3000 sound coding strategy or ACE strategy with lower stimulation

Sponsors

Royal Victoria Eye and Ear Hospital
CollaboratorOTHER_GOV
Cochlear
CollaboratorINDUSTRY
The Hearing Cooperative Research Centre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Adult (\>18 years) cochlear implant recipients 2. Implanted with the CI500, CI24RE and Nucleus 24 Series and CI422 cochlear implants. 3. User of commercially available Freedom, CP810 or CP900 series sound processor 4. User of the ACE strategy or MP3000 strategy 5. At least 3 months experience with the cochlear implant 6. Native speaker in the language used to assess speech perception performance 7. Willingness to participate in and to comply with all requirements of the protocol

Exclusion criteria

1. Additional handicaps that would prevent participation in evaluations 2. Unrealistic expectations on the part of the subject, regarding the possible benefits, risks and limitations that are inherent to the procedure and investigational device

Design outcomes

Primary

MeasureTime frameDescription
Word recognition scores in quietTesting over 18 weeksWord recognition scores in quiet for i) MP3000 strategy compared to default ACE strategy and ii) lower rate stimulation for ACE strategy
Sentence recognition scores in quietTesting over 18 weeksSentence recognition scores in quiet for i) MP3000 strategy compared to ACE strategy and ii) lower rate stimulation for ACE strategy

Secondary

MeasureTime frameDescription
Fundamental frequency (F0) discriminationTesting over 18 weeksF0 discrimination for MP3000 strategy compared to the ACE baseline
Speech intelligibility and helpfulness subjective ratingsTesting over 18 weeksFor MP3000 strategy compared to the default ACE baseline
Sentence in noise scoresTesting over 18 weeksComparison of MP3000 program with Spatial NR and NR3 enabled versus disabled.

Countries

Australia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026